future of glp-1 drugs The revolution: What UAB researchers are discovering about how these work The future of GLP-1 drugs

Karwi QG, Biswas D, Pulinilkunnil T, Lopaschuk GD

This marked a turning point, shifting GLP-1 agonists from diabetes-focused therapies to primary obesity treatments

Elena Volpi Reza Nazemi, Satoshi Fujita Muscle tissue changes with aging PMC

On the basis of results of the most recent CVOTs (DAPA-HF, DAPA-CKD, EMPEROR-R), the FDA has approved dapagliflozin (2020) and empagliflozin (2021) to reduce risk for CV death and HF hospitalization in adults with HF and reduced ejection fraction regardless of whether they have diabetes [24, 25]

Weekly subcutaneous injections currently offer the most reliable pharmacokinetics, bioavailability, and efficacy, producing consistent weight-loss outcomes and strong cardiovascular benefits

That benchmark is largely settled